Table 2.
Univariate analysis of the survival of 63 patients with nasopharyngeal carcinoma
| Variable | n | 5-year OS (%) | P-value | 5-year CSS (%) | P-value |
|---|---|---|---|---|---|
| Age | |||||
| <65years | 32 | 83.3 | 0.004 | 83.3 | 0.096 |
| ≥65years | 31 | 39.6 | 55.9 | ||
| Histology (WHO) | |||||
| Type I | 10 | 60.0 | 0.785 | 60.0 | 0.358 |
| Type II–III | 53 | 62.0 | 73.2 | ||
| ECOG PS | |||||
| 0–1 | 56 | 66.1 | <0.001 | 75.1 | 0.001 |
| 2 | 7 | 28.6 | 33.3 | ||
| T stage | |||||
| 1–2 | 31 | 66.3 | 0.220 | 75.8 | 0.170 |
| 3–4 | 32 | 57.4 | 67.0 | ||
| N stage | |||||
| 0 | 13 | 64.8 | 0.926 | 81.5 | 0.448 |
| 1–3 | 50 | 61.4 | 69.0 | ||
| N stage | |||||
| 0–2 | 57 | 61.0 | 0.789 | 71.5 | 0.819 |
| 3 | 6 | 66.7 | 66.7 | ||
| Chemotherapy | |||||
| Yes | 52 | 71.8 | <0.001 | 78.2 | 0.010 |
| No | 11 | 0 | 32.0 | ||
| Radiation type | |||||
| 3D-CRT | 43 | 59.7 | 0.470 | 72.7 | 0.926 |
| IMRT | 20 | 63.4 | 63.4 | ||
| Interim assessment by RECIST | |||||
| CR | 7 | 71.4 | 0.518 | 100 | 0.108 |
| Non-CR | 56 | 60.1 | 67.3 | ||
| Interim assessment of primary lesion | |||||
| CR | 10 | 70.0 | 0.633 | 87.5 | 0.346 |
| PR | 33 | 60.8 | 69.3 | ||
| SD | 20 | 58.7 | 66.9 | ||
| Interim assessment of primary lesion | |||||
| CR + PR | 43 | 62.5 | 0.451 | 72.4 | 0.431 |
| SD | 20 | 58.7 | 66.9 | ||
| Interim LN size | |||||
| <10 mm | 32 | 69.8 | <0.001 | 78.8 | <0.001 |
| ≥10 mm to <15 mm | 21 | 73.0 | 82.5 | ||
| ≥15 mm | 10 | 12.5 | 25.0 | ||
| Interim LN size | |||||
| Small group (<15 mm) | 53 | 70.5 | <0.001 | 80.0 | <0.001 |
| Large group (≥15 mm) | 10 | 12.5 | 25.0 | ||
| Total | 63 | 61.6 | 71.0 | ||
OS = overall survival, CSS = cause-specific survival, WHO = World Health Organization, ECOG = Eastern Cooperative Oncology Group, PS = performance status, 3D-CRT = 3D conformal radiation therapy, IMRT = intensity-modulated radiation therapy, CR = complete response, PR = partial response, SD = stable disease, LN = lymph node.